Skip to main content

    Main navigation

    • Investors
    • About
    • News
    • Contact us
    • Egoo.health
    • en
    • sv
Home

Main navigation

  • Investors
  • About
  • News
  • Contact us
  • Egoo.health
  • en
  • sv
 

Investors

+

Main navigation

Main navigation

  • News - Press releases
  • Financial Calendar
  • Financial reports
    • IPO and listning documents
  • Corporate governance
    • Articles Of Association
    • AGM and Extraordinary general meetings
      • Extraordinary Shareholders Meeting 19 November
      • Extraordinary general meeting January 2020
      • Annual General Meeting, May 20, 2020
    • Auditor
    • Election committee
    • Certified adviser
  • Share information
    • Major shareholders
    • Sharecapital
    • Incentive programme
    • Dividend Policy
    • Warrants (TO)
  • Board
  • Management
  • Insiders
  • IR Contact
  • Presentations

Warrants (TO)

The company has 4,472,600 issued warrants (TO1). Two (2) warrants entitle to subscribe for one (1) new share during the period 3 – 31 May 2021 at a price per share of SEK 17.50.

Upon full exercise of the TO1 warrants, the company will raise approximately MSEK 39.1 before deduction of issuance costs of approximately MSEK 1.2, and the share capital will be increased by approximately SEK 178,904.

Qlife

Qlife Holding AB
Hamntorget 3
SE-252 21 Helsingborg, Sweden
info@egoo.health

Links

  • About
  • Investors
  • Egoo.health

Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hospital platform.